Table 1

Concentration of Cyclophilin-like Activity in Synovial Fluids (Knee Punctures) and Disease Parameters

DiseasePatient initialsCyclophilin concentration*Synovial fluid cell countNeutrophilsIgMRFDuration of joint swelling
nMcc 103/ml%wk
RABE15922,70092+<1
RAPF‡  <2 1,20068+   4
RAHS10025,60094<1
RAMK 8720,50089+<1
RAMA23732,40096<1
RAFB 4816,30085+   2
RAGL24253,50096<1
RABR 1110,60080+   4
RAHR 3314,80084+   3
RASD 8922,60090+   1
RAPA 2413,00079+   3
RAWA, left§11731,70096+<1
RAWA, right§ 4924,60088+<1
RAHG 13 9,70078+>4
RAFH 3013,20082   4
RALR 7020,20087+   2
RAKM 8923,40090   1
RAHN 2916,40083+ 4
RALA 2815,10080>4
RAHH 2411,60078>4
RAKK 9223,40090+<1
RAKL57368,20092+<1
RANN10527,30090+<1
RAKP 1711,00088+   2
RAPM14732,60094+<1
RAAA70582,90096<1
RAEM11030,80091+<1
OAHU<2  <100NA‖>4
OASN<2  <100   NA>4
OASL<2     120   NA>4
OAPE<2  <100   NA   4
OAKR<2  <100   NA>4
  • *  Concentrations were obtained from a calibration curve with cyclophilin B (see text), and are thus based on the assumption that the PPlase activity is due to an enzyme with specific activity similar to cyclophilin B.  

  •  Treatment with recombinant human IL1 receptor antagonist.  

  • §  SF from patient WA was first taken from the left knee and subsequently intraarticular cortisone instillation was given into that knee. 24 h later, SF from the right knee was taken.  

  •  NA, not applicable.